A Framework for Addressing Structural Uncertainty in Decision Models
暂无分享,去创建一个
Karl Claxton | Simon G Thompson | Laura Bojke | Christopher H Jackson | Linda D Sharples | L. Sharples | K. Claxton | C. Jackson | S. Thompson | L. Bojke
[1] Jonathan Karnon,et al. A Critique and Impact Analysis of Decision Modeling Assumptions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] Jonathan Karnon,et al. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.
[3] L. Sharples,et al. Bayesian evidence synthesis to extrapolate survival estimates in cost‐effectiveness studies , 2006, Statistics in medicine.
[4] Miguel A Negrín,et al. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach. , 2008, Journal of health economics.
[5] Karl Claxton,et al. Eliciting distributions to populate decision analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] Louise B Russell,et al. Comparing Model Structures in Cost-Effectiveness Analysis , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] David R. Anderson,et al. Model selection and multimodel inference : a practical information-theoretic approach , 2003 .
[8] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[9] David Draper,et al. Assessment and Propagation of Model Uncertainty , 2011 .
[10] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[11] Roger M. Cooke,et al. Expert judgment in maintenance optimization , 1992 .
[12] A A Stinnett,et al. Estimating CE Ratios under Second-order Uncertainty , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] Karl Claxton,et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[15] S. Palmer,et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. , 2004, Health technology assessment.
[16] Andrea Tancredi,et al. A Bayesian model averaging approach for cost-effectiveness analyses. , 2009, Health economics.
[17] Simon G Thompson,et al. Structural and parameter uncertainty in Bayesian cost-effectiveness models , 2010, Journal of the Royal Statistical Society. Series C, Applied statistics.
[18] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .
[19] M. Granger Morgan,et al. Graphical Communication of Uncertain Quantities to Nontechnical People , 1987 .
[20] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[22] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[23] L. Sharples,et al. Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction , 2010, The international journal of biostatistics.
[24] M. Clyde,et al. Model Uncertainty , 2003 .
[25] S. Chick,et al. A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.
[26] Simon G Thompson,et al. Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.
[27] David J Spiegelhalter,et al. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.
[28] R. Cooke. Experts in Uncertainty: Opinion and Subjective Probability in Science , 1991 .
[29] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[30] David J Spiegelhalter,et al. Bias modelling in evidence synthesis , 2009, Journal of the Royal Statistical Society. Series A,.
[31] Masahiro Kokai,et al. Synapse alteration in hippocampal CA3 field following entorhinal cortex lesion , 1997, Journal of the Neurological Sciences.
[32] Christian Genest,et al. Combining Probability Distributions: A Critique and an Annotated Bibliography , 1986 .
[33] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[34] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[35] Hans-Christoph Diener,et al. European Stroke Prevention Study 2. Efficacy and safety data. , 1997, Journal of the neurological sciences.
[36] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.
[37] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[38] David Turner,et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. , 2004, Health economics.
[39] M Sculpher,et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. , 2006, Health technology assessment.